Tag Archive

Alnylam Receives Orphan Drug Designations in the European Union for ALN-AT3, an RNAi Therapeutic in Development for the Treatment of Hemophilia

In Press Release by CecileAugust 11, 2014Leave a Comment

August 7th, 2014 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal …

View Post

Alnylam Reports Initial Positive Top-Line Data from Phase 1 Clinical Trial with ALN-AT3, an RNAi Therapeutic Targeting Antithrombin (AT) in Development for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)

In Press Release by CameronMay 14, 2014Leave a Comment

Single, Lowest Dose Group of ALN-AT3 Achieves Statistically Significant Knockdown of AT and Increase in Thrombin Generation in “Part A” of Phase 1 Study in …

[[ Whitepaper ]] Connecting With Rare Disease Patient Communities: Patient Advocates

[[Whitepaper ]] Disruptive Innovation in Rare Disease Markets

Choosing the Right Channel Strategy for Specialty Product Success

[Whitepaper] Challenging Conventional Patient Recruitment and Care Strategies for Rare Disease Studies

[[whitepaper]] The New Reality: Maximizing Value in Rare Disease Launches

What’s New in Rare Cancer Research? (Spoiler Alert: A Lot!)

Tag Archive

Alnylam Receives Orphan Drug Designations in the European Union for ALN-AT3, an RNAi Therapeutic in Development for the Treatment of Hemophilia

Alnylam Reports Initial Positive Top-Line Data from Phase 1 Clinical Trial with ALN-AT3, an RNAi Therapeutic Targeting Antithrombin (AT) in Development for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)

Categories